Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Aug 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-08-15

Reporting Person: Paulsen Gisela (President & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-15	Common Stock, no par value	A	175000	—	Acquired	191500	Direct
2022-08-15	Common Stock, no par value	A	350000	—	Acquired	541500	Direct

Footnotes

F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service from the date of grant until the vesting date.

F2: The Restricted Stock Units shall vest on January 1, 2024 based on the achievement of a pre-determined financial objective related to the Issuer's available cash.